...
首页> 外文期刊>Malaria Journal >Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases
【24h】

Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases

机译:Atovaquone-Proguanil治疗进口性单纯性恶性疟原虫疟疾:553例前瞻性观察研究

获取原文
           

摘要

Background Each year, thousands of cases of uncomplicated malaria are imported into Europe by travellers. Atovaquone-proguanil (AP) has been one of the first-line regimens used in France for uncomplicated malaria for almost ten years. While AP’s efficacy and tolerance were evaluated in several trials, its use in “real life” conditions has never been described. This study aimed to describe outcome and tolerance after AP treatment in a large cohort of travellers returning from endemic areas. Methods Between September 2002 and January 2007, uncomplicated malaria treated in nine French travel clinics with AP were followed for 30 days after AP initiation. Clinical and biological data were collected at admission and during the follow-up. Results A total of 553 patients were included. Eighty-eight percent of them were born in Africa, and 61.8% were infected in West Africa, whereas 0.5% were infected in Asia. Migrants visiting friends and relatives (VFR) constituted 77.9% of the patients, the remainder (32.1%) were backpackers. Three-hundred and sixty-four patients (66%) fulfilled follow-up at day 7 and 265 (48%) completed the study at day 30. Three patients had treatment failure. One-hundred and seventy-seven adverse drug reactions (ADR) were reported during the follow-up; 115 (77%) of them were digestive ADR. Backpackers were more likely to experiment digestive ADR compared to VFR (OR?=?3.8; CI 95% [1.8-8.2]). Twenty patients had to be switched to another regimen due to ADR. Conclusion This study seems to be the largest in terms of number of imported uncomplicated malaria cases treated by AP. The high rate of reported digestive ADR is striking and should be taken into account in the follow-up of patients since it could affect their adherence to the treatment. Beside AP, artemisinin combination therapy (ACT) is now recommended as first-line regimen. A comparison of AP and ACT, in terms of efficacy and tolerance, would be useful.
机译:背景技术每年,成千上万的无并发症疟疾病例被旅行者进口到欧洲。近十年来,Atovaquone-Proguanil(AP)一直是法国用于单纯性疟疾的一线治疗方案之一。虽然AP的功效和耐受性已在几项试验中进行了评估,但从未描述其在“现实生活”条件下的使用。这项研究的目的是描述一大批从流行地区返回的旅行者接受AP治疗后的结果和耐受性。方法在2002年9月至2007年1月之间,在9例法国旅行诊所接受AP治疗的单纯性疟疾发生后30天内进行了随访。在入院时和随访期间收集临床和生物学数据。结果共纳入553例患者。其中88%的人出生于非洲,而61.8%的人感染于西非,而0.5%的人感染于亚洲。探亲访友(VFR)的患者占77.9%,其余(32.1%)是背包客。在第7天,有364例患者(66%)接受了随访,在第30天完成了研究,其中265例(48%)完成了研究。三例患者治疗失败。随访期间报告了147例药物不良反应(ADR)。其中115例(77%)是消化不良药物。与VFR相比,背包客更倾向于尝试消化性ADR(OR?=?3.8; CI 95%[1.8-8.2])。由于ADR,二十名患者不得不改用另一种方案。结论就AP治疗的输入的简单性疟疾病例而言,这项研究似乎是最大的。报告的消化不良不良反应发生率很高,在患者的随访中应予以考虑,因为这可能会影响他们对治疗的依从性。除了AP,现在推荐使用青蒿素联合治疗(ACT)作为一线治疗方案。在功效和耐受性方面比较AP和ACT会很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号